Becton Dickinson and Co

Becton Dickinson and Co(BDX)股票分析

$191.750

-1.994 (-1.04%)收盘时

Loading chart…
最高
195.990
开盘
194.420
成交量加权均价
192.65
成交量
1.41M
市值
66.74B
最低
190.210
成交额
272.15M
企业价值/息税折旧摊销前利润(TTM)
12.68

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

AI 分析 of Becton Dickinson and Co (BDX)

买入

Becton Dickinson (BDX) is a good buy right now due to its current price of $191.75, which is below the average analyst price target of $200, suggesting potential upside. The stock has a strong gross margin of 46.76% and a forward P/E ratio of 13.72, indicating solid profitability and reasonable valuation. However, the main risk is the recent dip in net income, with a reported loss of $31 million in Q2 2026, which could impact future performance.

分析师评级(15)

上行空间 +0.46%
买入
10 买入
5 持有
0 卖出
当前: 191.75
最低
157.00
平均
192.64
最高
232.00

Barclays

2026-10-07

目标价

$165

减持

BofA

2026-08-31

目标价

$200

中性

RBC Capital

2026-08-13

目标价

$190

Sector Perform

Citi

2026-08-13

目标价

$208

买入

RBC Capital

2026-08-07

目标价

$180

Sector Perform

估值指标

Becton Dickinson and Co(BDX)当前预期市盈率为 13.72,5 年平均预期市盈率为 17.19。

预期市盈率

合理
5 年均值 P/E
17.19
当前P/E
13.72
高估
20.85
低估
13.52

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
14.11
当前EV/EBITDA
12.68
高估
16.40
低估
11.82

预期市销率

合理
5 年均值 P/S
3.18
当前P/S
2.67
高估
3.76
低估
2.59

Alphio AI 对 BDX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BDX

$193.53

情景价格

基

基准

基准 · 50%BDX

$172.62

情景价格

悲

悲观

悲观 · 25%BDX

$171.68

情景价格

持有 BDX 的大户

J

John W. Bristol & Co., Inc.

+ 持有BDX

+6.49%

3个月收益率

V

Veritas Asset Management LLP

+ 持有BDX

+5.30%

3个月收益率

J

James Hambro & Partners LLP

+ 持有BDX

+4.65%

3个月收益率

B

Beutel Goodman & Company Ltd.

+ 持有BDX

+4.35%

3个月收益率

F

Fort Washington Investment Advisors, Inc.

+ 持有BDX

+4.29%

3个月收益率

G

Guyasuta Investment Advisors, Incorporated

+ 持有BDX

+3.73%

3个月收益率

事件时间线

2026-10-07 (ET)

08:30:00

BD Reports Positive Nine-Month Results for Revello Vascular Covered Stent

2026-10-06 (ET)

07:00:00

Becton Dickinson Partners with U.S. Government for $19B Manufacturing Expansion

2026-09-21 (ET)

17:00:00

Becton, Dickinson Appoints Arthur Hu as Chief Information Officer

2026-08-12 (ET)

07:00:00

Becton Dickinson Completes Enrollment in PREVENT Clinical Trial

资讯

BDX 常见问题 —— 由 Alphio AI 解答

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Becton Dickinson (BDX) is a good buy right now due to its current price of $191.75, which is below the average analyst price target of $200, suggesting potential upside. The stock has a strong gross margin of 46.76% and a forward P/E ratio of 13.72, indicating solid profitability and reasonable valuation. However, the main risk is the recent dip in net income, with a reported loss of $31 million in Q2 2026, which could impact future performance.

15 analysts cover BDX: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 192.64.

range_bonder2026/9/16

Beldex @BeldexCoin recently published two research pieces, and I think they are interesting to look at together. One is about age verification: you only need to prove you are over 18, without handing over your birthday, identity, and nationality all at once. At the same time, it checks that the credential signature is real, that the age is actually derived from that birthday, that the same number is locked in the commitment, and that this number is not below 18. In the end, the other party only gets one result: you meet the age requirement. This is still research for now. Beldex Research Labs is next trying Bulletproof to make the proof smaller and push verification cost down further. It has not yet become a ready feature in BChat or the wallet. The other is VRF consensus. Beldex's current PoS already has a layer of random validator selection. What VRF aims to add is verifiable randomness: everyone can later verify whether the result of who got selected followed the rules, while before the draw it is harder to predict in advance who the next batch will be. The team currently places the VRF-based PoS hardfork in Q1 2027. This is also a later upgrade, not something already fully switched over on mainnet now. One is dealing with how much identity information should be exposed, and the other is dealing with how randomness in consensus should be proven. These two research lines at Beldex are actually quite consistent in direction: provide enough information, and avoid exposing extra information as much as possible.

展开
注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易